133 Southcenter Court
Gentris Corporation is a leading global provider of applied, clinical, genomic biomarker and biorepository services. As pioneers in the field of pharmacogenomics, Gentris assists pharmaceutical companies and clinical research organizations to effectively integrate pharmacogenomics into their drug development programs to deliver safer, more effective drugs to market more quickly.
To enable our clients to quickly obtain and translate high quality genomic biomarker results into safer, more effective medicines that improve the standard of care for patients globally.
Gentris was founded in 2001 as a pharmacogenomics (PGx) services and diagnostics (Dx) products company. The initial founders created a robust infrastructure and quality system to support the delivery of consistent, regulatory-compliant services. In 2007, the diagnostics division was spun off as Paragon Dx while Gentris Corporation maintained its specialized focus of providing PGx testing services for clinical trials. Since its inception, Gentris has supported over 1,000 Phase I-Phase III clinical trials, domestically and globally, and developed over 400 assays de novo. An Integrated Biorepository was created in 2010 to preserve the integrity of clinical samples and enhance their value by incorporating validated sample handling and storage capabilities with PGx testing services. Gentris currently has over 60 employees at its 25,000 sq. ft. facility in Morrisville, NC.
Quality, expertise, and customer satisfaction drive Gentris’ core business model in integrated genomic biomarker solutions and biorepository services. We provide seamless and dynamic coupling of comprehensive project life cycle management and full logistics support with the power of tested platforms for sample extraction and purification, genotyping, gene expression analysis, microarray analysis, tumor profiling, and custom assay development and validation.
Gentris is in the process of opening a facility in Shanghai, China located in the Pharma Valley area of Zhiangjiang Hi-Tech Park, the oldest and largest science park in China. This new facility allows Gentris to be a global provider of pharmacogenomics and biorepository services for all phases of clinical development. The launch of the satellite laboratory in Shanghai is planned for early 2013, beginning with biorepository services. Gentris China will provide the same U.S. FDA-compliant PGx testing and biorepository services to U.S. and E.U. pharmaceutical clients with management and oversight by Gentris Corporation in the USA.
Gentris’ Solutions and Value Proposition
• Genotyping and Gene Expression
• Next Generation Sequencing
• Patient Inclusion, Exclusion, Stratification
• Phase I-IV, End-point, and Retrospective Analysis
• Study Design, IRB Development
• CLIA, GLP, ICH E15 Compliant Services
Biorepository and Sample Management Services
• Biorepository Management and Support
• Full Scale Nucleic Acid Extraction and Purification Services
• Worldwide Shipping, Coordination, Monitoring
• Integrated Sample Receipt, Accessioning, Tracking, LIMS
• CAP Accredited, ISBER Guideline Compliant Services
Rick Williams, Chief Executive Officer
L. Scott Clark, Ph. D., Chief Scientific Officer
Stacey O’Neill, M.D., Ph.D., Medical Director
Carrie Browning, Vice President, Business and Client Development